These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 16377423)

  • 1. Prostate-only not dead?
    Chuba PJ; Aref A
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):329-30. PubMed ID: 16377423
    [No Abstract]   [Full Text] [Related]  

  • 2. This paper evaluates the natural history of prostate cancer in heterogeneous cohort of men treated with HT.
    Yossepowitch O
    Eur Urol; 2007 Aug; 52(2):453. PubMed ID: 17674435
    [No Abstract]   [Full Text] [Related]  

  • 3. [Reevaluation of MAB therapy and progress of endocrine therapy].
    Klotz L; Payne H; Gillatt D; Keane T; Morris C; Akaza H; Hirao ; Akakura K; Fukagai T
    Gan To Kagaku Ryoho; 2005 May; 32(5):705-28. PubMed ID: 15934164
    [No Abstract]   [Full Text] [Related]  

  • 4. [Interest of the radiotherapy-hormonotherapy association in the treatment of the high-risk prostate cancer].
    Bolla M; Fourneret P; Descotes JL
    Bull Cancer; 2008 Dec; 95(12):1213-8. PubMed ID: 19091656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Despite PSA screening and the control by radical prostatectomy, patients treatment fails and have a PSA recurrence.
    Lotan Y
    Eur Urol; 2007 Aug; 52(2):453-4. PubMed ID: 17674436
    [No Abstract]   [Full Text] [Related]  

  • 6. In regards to Roach et al. defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference (Int J Radiat Oncol Biol Phys 2006;65:965-974).
    Cheung R
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1274; author reply 1274-5. PubMed ID: 17145548
    [No Abstract]   [Full Text] [Related]  

  • 7. Outcome analysis of 300 prostate cancer patients treated with neoadjuvant androgen deprivation and hypofractionated radiotherapy.
    Higgins GS; McLaren DB; Kerr GR; Elliott T; Howard GC
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):982-9. PubMed ID: 16750310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cancer of the prostate: importance of androgen deprivation and radiotherapy].
    Rentsch CA; Aebersold DM; Merz V; Studer UE
    Rev Med Suisse; 2005 May; 1(19):1303-6. PubMed ID: 15962630
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of postradiotherapy PSA patterns and correlation with 10-year disease free survival outcomes for prostate cancer.
    Zelefsky MJ; Ben-Porat L; Chan HM; Fearn PA; Venkatraman ES
    Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):382-8. PubMed ID: 16965990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy.
    Palma D; Tyldesley S; Pickles T;
    Cancer; 2008 May; 112(9):1941-8. PubMed ID: 18338814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Definitive conformal radiotherapy for localized high-risk prostate cancer: a long-term follow-up study with PSA course.
    Bruns F; Franzki C; Wegener G; Karstens JH
    Anticancer Res; 2007; 27(4A):1847-51. PubMed ID: 17649783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
    Soga N; Onishi T; Arima K; Sugimura Y
    Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Combined radiotherapy and hormone therapy in non-metastatic adenocarcinoma of prostate].
    Lopez S; Simon JM; Mazeron JJ
    Bull Cancer; 2009 Mar; 96(3):261-70. PubMed ID: 19318304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [High risk prostate cancer results of one year RT-HT].
    Delaporte V; Muracciole X; Lechevalier E; Bastide C; Cowen D; Rossi D; Coulange C
    Prog Urol; 2005 Dec; 15(6 Suppl 1):1256-61. PubMed ID: 16734214
    [No Abstract]   [Full Text] [Related]  

  • 15. Rising prostate-specific antigen values during neoadjuvant androgen deprivation therapy: The importance of monitoring.
    Niblock P; Pickles T;
    Int J Radiat Oncol Biol Phys; 2006 May; 65(1):59-64. PubMed ID: 16413696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Surgical and medical treatment for localized prostate cancer].
    Kawai K
    Gan To Kagaku Ryoho; 2007 Jul; 34(7):1002-5. PubMed ID: 17637535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duration of androgen suppression in prostate cancer.
    Badiozamani KR
    N Engl J Med; 2009 Sep; 361(12):1212; author reply 1212-3. PubMed ID: 19759384
    [No Abstract]   [Full Text] [Related]  

  • 19. How early is early: androgen deprivation for prostate-specific antigen relapse in prostate cancer.
    Duchesne GM; Syme R; Howell D
    J Clin Oncol; 2006 Jun; 24(18):2964; author reply 2965. PubMed ID: 16782936
    [No Abstract]   [Full Text] [Related]  

  • 20. A call for more with a desire for less: pelvic radiotherapy with androgen deprivation in the treatment of prostate cancer.
    Pollack A
    J Clin Oncol; 2003 May; 21(10):1899-901. PubMed ID: 12743140
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.